Mehrdad Abedi, MD
Hematology & Oncology · Sacramento, CANPI 1467459222
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $518,078 of the $612,525 with a category attached, or 84.6%. 14 manufacturers reported payments, led by Gilead at 32.0% of the total. Reporting peaked in 2019 at $171,529 and has fallen 79.9% since, to $34,505 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 339 payments — averaging $1806.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$196K
- AbbVie$181K
- E.r. Squibb & Sons, L.L.C.$121K
- Bristol Myers Squibb$80K
- Seagen Inc.$17K
- Takeda Pharmaceuticals U.S.A., Inc.$16K
- plus $2K from 8 others
Across 207 payments — averaging $11,273 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- National Marrow Donor Program$800K
- Sanofi US Services Inc.$745K
- Gilead$562K
- Bioverativ Therapeutics Inc.$93K
- Autolus Inc$40K
- Amgen$39K
- plus $53K from 2 others
What the payments were for
- Consulting fees$10,9802%
- Speaking & faculty fees$518,07885%
- Travel & lodging$74,93012%
- Food & beverage$8,4061%
- Education$1300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 107 | $195,730 |
| AbbVie | 87 | $180,781 |
| E.r. Squibb & Sons, L.L.C. | 62 | $121,159 |
| Bristol Myers Squibb | 52 | $80,158 |
| Seagen Inc. | 12 | $16,968 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $16,120 |
| Sanofi | 1 | $1,006 |
| Genentech USA, Inc. | 2 | $165 |
| Johnson & Johnson | 2 | $145 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $73 |
| Astellas Pharma US Inc | 1 | $65 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$612,525 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Posaconazole | 17 | $28,355 |
| Acyclovir | 66 | $1,547 |
| Ondansetron Hcl | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Sacramento
- Nitin RohatgiSacramento$814K
- Adam GiermaszSacramento$438K
- Scott ChristensenSacramento$349K
- David GandaraSacramento$336K
- Joseph TuscanoSacramento$258K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.